Ken Griffin’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-157,217
| Closed | -$891K | – | 13912 |
|
|
2025
Q3 | $891K | Buy |
157,217
+27,142
| +21% | +$139K | ﹤0.01% | 7783 |
|
|
2025
Q2 | $496K | Buy |
130,075
+91,412
| +236% | +$284K | ﹤0.01% | 8661 |
|
|
2025
Q1 | $102K | Buy |
+38,663
| New | +$126K | ﹤0.01% | 11430 |
|
|
2024
Q4 | – | Sell |
-525,964
| Closed | -$2.01M | – | 15278 |
|
|
2024
Q3 | $2.4M | Sell |
525,964
-209,440
| -28% | -$1.01M | ﹤0.01% | 5188 |
|
|
2024
Q2 | $3.2M | Buy |
735,404
+158,491
| +27% | +$696K | ﹤0.01% | 4471 |
|
|
2024
Q1 | $2.9M | Buy |
576,913
+437,417
| +314% | +$2.45M | ﹤0.01% | 4857 |
|
|
2023
Q4 | $875K | Buy |
139,496
+134,506
| +2,696% | +$770K | ﹤0.01% | 6942 |
|
|
2023
Q3 | $35.5K | Buy |
4,990
+4,937
| +9,315% | +$38.9K | ﹤0.01% | 12141 |
|
|
2023
Q2 | $540 | Sell |
53
-93,069
| -100% | -$971K | ﹤0.01% | 14092 |
|
|
2023
Q1 | $845K | Sell |
93,122
-55,586
| -37% | -$407K | ﹤0.01% | 7163 |
|
|
2022
Q4 | $1.07M | Buy |
148,708
+120,772
| +432% | +$738K | ﹤0.01% | 6697 |
|
|
2022
Q3 | $182K | Sell |
27,936
-19,298
| -41% | -$103K | ﹤0.01% | 10502 |
|
|
2022
Q2 | $228K | Buy |
47,234
+15,740
| +50% | +$77.9K | ﹤0.01% | 10428 |
|
|
2022
Q1 | $179K | Buy |
+31,494
| New | +$155K | ﹤0.01% | 11660 |
|
|
2020
Q3 | – | Sell |
-54,277
| Closed | -$399K | – | 10658 |
|
|
2020
Q2 | $399K | Buy |
+54,277
| New | +$477K | ﹤0.01% | 7448 |
|
|
2018
Q3 | – | Sell |
-16,828
| Closed | -$95K | – | 9633 |
|
|
2018
Q2 | $95K | Buy |
+16,828
| New | +$173K | ﹤0.01% | 8262 |
|
Ken Griffin's SCPH Position: Q4 2025 in Review
Ken Griffin sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 157,217 shares — an estimated $891K sold.
Ken Griffin first reported a position in SCPH in Q2 2018 and held it in 16 quarters. The position peaked at $3.2M in Q2 2024. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Ken Griffin reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Ken Griffin sold 157,217 scPharmaceuticals shares in Q4 2025, an estimated $891K.
- Ken Griffin first reported a position in scPharmaceuticals in Q2 2018 and held it in 16 quarters.
- Ken Griffin's scPharmaceuticals position peaked at $3.2M in Q2 2024.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.